论文部分内容阅读
目的探讨腺病毒介导的突变kras基因修饰的树突状细胞疫苗在体内的抗肿瘤作用。方法将突变kras基因修饰的DC经腹腔注射免疫小鼠(5×105/只),1次/周,共2次,随后将肿瘤细胞接种于皮下,观察DC能否诱发机体的免疫保护。结果突变kras基因修饰的DC疫苗组Lewis肺癌(3LL)移植瘤生长明显延缓,肿瘤体积显著低于空载体组、DC组和对照组(P<0.05),而抑瘤率显著高于空载体组、DC组和对照组(P<0.05)。突变kras基因修饰的DC疫苗组Lewis肺癌(3LL)移植瘤肺转移率(2/10,20%)显著低于空载体组(6/10,60%)、DC组(6/10,60%)和对照组(8/10,80%,P<0.05);肺部转移灶数目亦显著少于空载体组、DC组和对照组(P<0.05)。结论突变kras基因修饰的DC疫苗能有效诱导机体产生特异的抗肿瘤免疫反应,抑制Lewis肺癌生长和远处转移。
Objective To investigate the anti-tumor effect of dendritic cell vaccine modified by adenovirus mediated kras gene in vivo. Methods Immunized mice (5 × 105 / mouse) were injected intraperitoneally with DCs modified by kras gene. The mice were inoculated subcutaneously twice a week for 2 times. Results The growth of Lewis lung carcinoma (3LL) transplanted with mutant kras gene was significantly delayed and the tumor volume was significantly lower than that of empty vector group, DC group and control group (P <0.05), but the tumor inhibition rate was significantly higher than that of blank vector group , DC group and control group (P <0.05). The lung metastasis rate of Lewis lung carcinoma (3LL) group was significantly lower than that of the blank vector group (6/10, 60%) and the DC group (6/10, 60% ) And control group (8/10, 80%, P <0.05). The number of lung metastases was also significantly less than that of the blank vector group, the DC group and the control group (P <0.05). Conclusion The mutant kras gene modified DC vaccine can effectively induce the body to produce specific anti-tumor immune response and inhibit the growth and distant metastasis of Lewis lung cancer.